StreetInsider.com News Articles

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

Tue, 06 Oct 2026 07:30:00 -0400

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their respective immunotherapy programs have been selected for poster presentations at the Society for Immunotherapy of Cancer (SITC) 41^th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.

The presentations will feature BriaCell’s personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro’s research on

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

Tue, 06 Oct 2026 07:30:00 -0400

The presentations will feature BriaCell’s personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro’s research on

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

Tue, 06 Oct 2026 07:30:00 -0400

The presentations will feature BriaCell’s personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro’s research on

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

Tue, 06 Oct 2026 07:30:00 -0400

The presentations will feature BriaCell’s personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro’s research on

BriaCell's Phase 3 breast cancer study clears seventh DSMB review

Mon, 14 Sep 2026 07:30:11 -0400

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL; TSX: BCT) announced that an independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive recommendation to continue the company's pivotal Phase 3 Bria-ABC study without modifications.

The DSMB, which meets quarterly in accordance with the study protocol, reported no safety or clinical concerns following its latest review of data from the trial. The study is evaluating Bria-IMT combined with an immune checkpoint inhibitor in patients with metastatic breast cancer (NCT06072612).

The Phase 3 study is being conducted under Fast Track designation granted by the U.S. Food and Drug Administration (FDA).

"We are very encouraged by

BriaCell's Phase 3 breast cancer study clears seventh DSMB review

Mon, 14 Sep 2026 07:30:11 -0400

The Phase 3 study is being conducted under Fast Track designation granted by the U.S. Food and Drug Administration (FDA).

"We are very encouraged by

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Mon, 14 Sep 2026 07:30:00 -0400

Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor
Seventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy approach
Phase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care,

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Mon, 14 Sep 2026 07:30:00 -0400

Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor
Seventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy approach
Phase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Mon, 14 Sep 2026 07:30:00 -0400

Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor
Seventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy approach
Phase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Mon, 14 Sep 2026 07:30:00 -0400

Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor
Seventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy approach
Phase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer

BriaCell adds Memorial Sloan Kettering to Phase 3 breast cancer trial

Tue, 08 Sep 2026 07:30:28 -0400

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL; TSX: BCT) announced that Memorial Sloan Kettering Cancer Center (MSK) has joined its ongoing pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer.

The trial, identified as NCT06072612, now spans more than 80 active clinical sites across 15 states. Other participating institutions include Penn Medicine's Abramson Cancer Center, Mayo Clinic, Northwestern University, Smilow Cancer Hospital at Yale New Haven, and Sylvester Comprehensive Cancer Center, among others.

The study, known as the Bria-ABC study, compares the Bria-IMT combination regimen against physician's choice of treatment in patients with advanced metastatic

BriaCell adds Memorial Sloan Kettering to Phase 3 breast cancer trial

Tue, 08 Sep 2026 07:30:28 -0400

The study, known as the Bria-ABC study, compares the Bria-IMT combination regimen against physician's choice of treatment in patients with advanced metastatic

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Tue, 08 Sep 2026 07:30:00 -0400

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)
BriaCell Phase 3 trial featured in Nature Medicine as “Eleven clinical trials that will shape medicine in 2026”

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in metastatic breast

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Tue, 08 Sep 2026 07:30:00 -0400

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)
BriaCell Phase 3 trial featured in Nature Medicine as “Eleven clinical trials that will shape medicine in 2026”

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Tue, 08 Sep 2026 07:30:00 -0400

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)
BriaCell Phase 3 trial featured in Nature Medicine as “Eleven clinical trials that will shape medicine in 2026”

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Tue, 08 Sep 2026 07:30:00 -0400

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)
BriaCell Phase 3 trial featured in Nature Medicine as “Eleven clinical trials that will shape medicine in 2026”

BriaCell Therapeutics Announces Pricing of Offering